Bacteria building resistance to moxifloxacin

Article

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers.

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers, according to Gita Sathpathy and co-workers at the All India Institute of Medical Sciences, New Dehli, India.

The records of 934 consecutive cases of bacterial corneal ulcers were retrospectively reviewed and culture and antibiotic sensitivity reports of corneal scrapings were analysed. Recorded parameters included age, sex, organism isolated and sensitivity, using Kirby-Bauer disc-diffusion, to moxifloxacin. The bacterial isolates that were resistant to moxifloxacin were examined in detail and their antibiotic sensitivity to other drugs was studied.

Of the 934 bacterial isolates, 913 (97.5%) were sensitive to moxifloxacin and 21 (2.25%) were found to be resistant. Of the 21 resistant isolates, eight were Staphylococcus albus, eight were Pseudomonas, two were Streptococcus viridians, one was Streptococcus pneumoniae, one was Staphylococcus aureus and one was E. coli. Of the eight Pseudomonas cases, six were found to be sensitive to polymyxin and five sensitive to amikacin. Out of the eight Staphylococcus, seven were sensitive to vancomycin.

The emergence of a resistance to moxifloxacin in bacteria isolated from corneal ulcers, indicates that the drug should not be used indiscriminately.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.